MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-09-2026
Coherus BioSciences P/E Ratio 2011-2026 | CHRS
Annual P/E Ratio Coherus BioSciences
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.35 | 7.76 | -0.879 | -1.8 | -3.25 | 10.2 | 14.3 | -4.06 | -2.45 | -9.2 | -2.2 | -2.11 | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 14.3 | -9.2 | 0.634 |
P/E Ratio of other stocks in the Biotechnology industry
| Issuer | P/E Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
-0.612 | - | 2.43 % | $ 254 M |  Germany |
 |
Alterity Therapeutics Limited
ATHE
|
-66.5 | $ 3.6 | 1.34 % | $ 8.66 B |  Australia |
 |
Aytu BioScience
AYTU
|
-1.16 | $ 2.66 | - | $ 16.7 M |  USA |
 |
BioNTech SE
BNTX
|
6.11 | $ 91.28 | - | $ 27.2 B | Germany |
 |
I-Mab
IMAB
|
-0.236 | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
55.7 | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
2.49 K | - | 2.54 % | $ 160 B |  France |
 |
Burford Capital Limited
BUR
|
12.2 | $ 4.48 | - | $ 736 M |  Britain |
 |
Biophytis SA
BPTS
|
-17.6 | - | -13.47 % | $ 169 M | France |
 |
Cerus Corporation
CERS
|
-31.7 | $ 1.85 | - | $ 353 M | USA |
 |
Midatech Pharma plc
MTP
|
-14.5 | - | -18.52 % | $ 27.3 M | Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-3.57 | - | -1.52 % | $ 24.7 M | USA |
 |
Acorda Therapeutics
ACOR
|
-0.0662 | - | -24.86 % | $ 820 K | USA |
 |
Celldex Therapeutics
CLDX
|
-7.88 | $ 31.37 | - | $ 2.08 B | USA |
 |
CollPlant Biotechnologies Ltd.
CLGN
|
-1.7 | $ 0.44 | - | $ 5.04 M |  Israel |
 |
Advaxis
ADXS
|
-0.0388 | - | -9.65 % | $ 45.9 M | USA |
 |
Adverum Biotechnologies
ADVM
|
-0.583 | - | - | $ 86.2 M | USA |
 |
CNS Pharmaceuticals
CNSP
|
-0.0669 | $ 2.32 | - | $ 1.03 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
38.8 | - | - | - |  Russia |
 |
Catalyst Pharmaceuticals
CPRX
|
14.2 | $ 24.98 | - | $ 3.05 B | USA |
 |
Corbus Pharmaceuticals Holdings
CRBP
|
-1.62 | $ 10.14 | - | $ 135 M | USA |
 |
Cardiff Oncology
CRDF
|
-2.54 | $ 1.58 | - | $ 106 M | USA |
 |
Curis
CRIS
|
-1.25 | $ 0.53 | - | $ 6.98 M | USA |
 |
Crinetics Pharmaceuticals
CRNX
|
-8.83 | $ 37.7 | - | $ 3.55 B | USA |
 |
CRISPR Therapeutics AG
CRSP
|
-7.54 | $ 49.15 | - | $ 4.42 B |  Schweiz |
 |
Aeterna Zentaris
AEZS
|
-4.94 | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
-0.00095 | - | -10.17 % | $ 12.2 K | USA |
 |
CytomX Therapeutics
CTMX
|
-53.6 | $ 4.4 | - | $ 607 M | USA |
 |
Citius Pharmaceuticals
CTXR
|
-0.614 | $ 0.86 | - | $ 5.79 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-3.48 | - | - | $ 1.01 B | USA |
 |
Cue Biopharma
CUE
|
-1.1 | $ 0.18 | - | $ 17.1 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-1.71 | - | - | $ 26.5 M | USA |
 |
DBV Technologies S.A.
DBVT
|
-19.2 | $ 20.36 | - | $ 2.84 B | France |
 |
AIkido Pharma
AIKI
|
-1.33 | - | 1.93 % | $ 17.4 M | USA |
 |
Aptose Biosciences
APTO
|
-0.0913 | - | -45.71 % | $ 1.2 M | Canada |
 |
Denali Therapeutics
DNLI
|
-7.19 | $ 19.38 | - | $ 3.19 B | USA |
 |
Dyadic International
DYAI
|
-4.27 | $ 0.87 | -2.8 % | $ 31.5 M | USA |
 |
Akero Therapeutics
AKRO
|
-12.9 | - | - | $ 3.67 B | USA |
 |
CureVac N.V.
CVAC
|
-8.58 | - | - | $ 867 M | Germany |
 |
Akari Therapeutics, Plc
AKTX
|
-467 | $ 3.54 | - | $ 238 B | Britain |
 |
Akouos
AKUS
|
-1.98 | - | 0.23 % | $ 488 M | USA |
 |
Entera Bio Ltd.
ENTX
|
-3.06 | $ 1.19 | - | $ 55.5 M | Israel |
 |
Equillium
EQ
|
-5.27 | $ 2.01 | - | $ 115 M | USA |
 |
Allakos
ALLK
|
-0.612 | - | - | $ 28.6 M | USA |
 |
Allena Pharmaceuticals
ALNA
|
-2.17 | - | 3.16 % | $ 1.9 M | USA |
 |
Alnylam Pharmaceuticals
ALNY
|
130 | $ 330.34 | - | $ 43.3 B | USA |
 |
Alpine Immune Sciences
ALPN
|
-4.65 | - | - | $ 2.17 B | USA |
 |
Fate Therapeutics
FATE
|
-1.37 | $ 1.19 | - | $ 141 M | USA |
 |
Aileron Therapeutics
ALRN
|
-0.608 | - | 10.36 % | $ 9.8 M | USA |